At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 159 enrolled
Drug / intervention
Caduetdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open Label Study To Evaluate Long Term Safety Of Caduet In Patient With Both Of Hypertension And Hypercholesterolemia, Or With Both Of Angina Pectoris And Hypercholesterolemia
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Aug 27, 2010·Updated Jan 28, 2021
In Brief
A Phase 4 clinical trial evaluating Caduet for Hypertension and 2 related conditions. Completed, enrolled 159 participants across 20 sites.
Detailed Summary
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension and hypercholesterolemia, or with both angina pectoris and hypercholesterolemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Hypercholesterolemia, Angina Pectoris
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedAug 2010
Primary CompletionFeb 2012
TodayJul 2026
First PostedAug 27, 2010
Enrollment StartAug 1, 2010
Primary CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.8 years ago
Interventions
Caduetdrug
One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks